Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
The link between HPV infection and neoplasia
2024-07-01

The link between HPV infection and neoplasia has been well established. HPV encodes two oncogenes (E6 and E7) that drive Dovitinib Lactate progression by controlling the functions of tumor suppressor proteins p53 and Rb [7]. HPV is associated with more than 99% of cervical CESC cases [8]. CESC remai
-
In our study we provide evidence
2024-06-28

In our study we provide evidence for the existence of an endosome-lysosomal pathway for the proteolytic degradation of AR triggered by its interaction with the ESCRT-I component TSG101. The following findings of this study support this notion: (1) We showed that TS101 interacts with endogenous or ec
-
A central question that arises in this discussion is
2024-06-28

A central question that arises in this discussion is whether enhanced neurobehavioral responses to food cues emerge as a consequence of weight gain, or whether there are intrinsic differences in the motivational responses to food cues that precede weight gain. In support of pre-existing differences,
-
These findings suggest that eventually more
2024-06-28

These findings suggest that eventually more than one 12/15-lipoxygenase isoform may play a role in human atherosclerosis. Humans have two 12-lipoxygenases and two 15-lipoxygenases which show different expression patterns, substrate specificities and stereo-selective metabolism [1]. However, in Floxu
-
Introduction Lipoxygenases LOXs are key enzymes
2024-06-28

Introduction Lipoxygenases (LOXs) are key enzymes that catalyze the polyunsaturated fatty acids (PUFAs) such as arachidic Eribulin (AA), linoleic acid (LA) and others unsaturated fatty acids (Brash, 1999). LOXs are expressed in immune, neural, epithelial, tumor cells and other cells (Claesson, 200
-
The ORR obtained with crizotinib
2024-06-28

The ORR obtained with crizotinib on our cohort was low compared to other studies, such as the prospective studies of A. Shaw et al. (ORR = 65% in second line), B. Solomon et al. (ORR = 74% in first line) and the more comparable large retrospective study of M. Duruisseaux et al. on the French CLINALK
-
CGP 57380 australia In this study we designed and synthesize
2024-06-28

In this study, we designed and synthesized two ALK PROTACs (degraders), 5 (MS4077) and 6 (MS4078), by linking ceritinib and pomalidomide [45] through two different linkers. Using human ALCL and NSCLC cells, we characterized both compounds in a battery of assays to demonstrate their effects on reduci
-
br Materials and Methods br Results In the Base
2024-06-28

Materials and Methods Results In the Base Analysis (53% of patients having access to the ALK test in both Current and Alternative Scenarios), a total of 16,583 patients were tested of whom 1,252 were assumed to be ALK-positive. A more extensive use of Ventana in the Alternative Scenario determ
-
br Materials and methods br Results br Discussion
2024-06-28

Materials and methods Results Discussion Competing financial interests Acknowledgements The work was partially supported by grants from the National Natural Science Foundation of China (Grant no. 31530053 and 31401424) and National Science and Technology Support Plan (Grant no. 2013BA
-
Thus far clinical data indicate that IDO inhibitors have
2024-06-28

Thus far, clinical data indicate that IDO1 inhibitors have manageable toxicity, albeit with a relatively short period of treatment in a small number of patients. KYN is a pluripotent mediator and key intermediate for the synthesis of a host of downstream KP metabolites that are implicated in inflamm
-
Although the effects of adenosine receptor signaling
2024-06-28

Although the effects of adenosine receptor signaling in acute renal IRI have been attributed to the generation of high concentrations of adenosine, we have recently reported an increase in kidney levels of both AMP and adenosine, with a concomitant fall in ATP and ADP. We have also previously demons
-
To assess relative metabolic activity
2024-06-28

To assess relative metabolic activity and proliferation of AR-C155858 mg attached to various substrates we used the MTT assay [29], [30]. In order to compare the metabolic activity of cells under the various conditions irrespective of the number or viability of the cells, we performed a PicoGreen D
-
br Introduction In myasthenia gravis MG autoantibodies
2024-06-28

Introduction In myasthenia gravis (MG), autoantibodies against the native AChR conformation cause loss of AChR at the neuromuscular junction and fatigable muscle weakness (Newsom-Davis et al., 1993). The AChR is a pentameric transmembrane protein, with two splice forms of the α-subunit, P3A− and
-
aristocort The presence of different LO splice variants was
2024-06-28

The presence of different 5-LO splice variants was first demonstrated in human aristocort tumour cells and in dimethyl sulfoxide-differentiated HL-60 cells [40] and a correlation between the 5-LO splicing pattern and the malignancy of the brain tumours was found. Later, other splice variants were id
-
The LOX hydroxide metabolites are
2024-06-27

The 15-LOX hydroxide metabolites are converted to secondary lipid mediators such as lipoxin A4 from 15-HETE and protectin D1/resolvin D1 from 17-HDoHE [45] (Fig. S3). Importantly, all of these secondary lipid mediators have anti-inflammatory and pro-resolving properties [46], [47], [48]. Lipoxin A4
16803 records 143/1121 page Previous Next First page 上5页 141142143144145 下5页 Last page